Patient who has received radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to treatment start, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 30% of the bone marrow was irradiatedXx_NEWLINE_xXReceived radiotherapy =< 28 days or limited field radiation for palliation =< 14 days prior to registration, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 25% of the bone marrow was irradiatedXx_NEWLINE_xXParticipants who have received radiotherapy =< 2 weeks prior to starting study drug, and who have not recovered to grade 1 or better from related side effects of such therapy (except alopecia and neuropathy) and/or in whom >= 25% of the bone marrow was irradiatedXx_NEWLINE_xXPrevious radiotherapy to 25% or more of the bone marrow and/or radiation therapy within 28 days prior to study entryXx_NEWLINE_xXPrior radiation therapy is allowed to < 25% of the bone marrow, but is not permitted within 28 days prior to study registrationXx_NEWLINE_xXPatient who has received radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 30-25% of the bone marrow was irradiatedXx_NEWLINE_xXPatient who has received radiotherapy =< 4 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia), and/or in whom >= 25% of the bone marrow was irradiatedXx_NEWLINE_xXReceipt of radiotherapy to >25 % of bone marrow.Xx_NEWLINE_xXPatients who have received radiation to more than 25% of marrow-bearing areasXx_NEWLINE_xXPrior radiation therapy encompassing >25% of skeletonXx_NEWLINE_xXNo prior radiation to > 25% of the marrow.Xx_NEWLINE_xXParticipant has received radiotherapy ?4 weeks or limited field radiation for palliation ?2 weeks prior to starting study drug, and who has not recovered to Grade 1 or better from related side effects of such therapy (with the exception of alopecia) and/or for whom ?30% of the bone marrow was irradiated.Xx_NEWLINE_xXPrior radiotherapy within 2 weeks of the first dose of study treatment; patients who have received radiation to more than 25% of the bone marrow are not eligible at any timeXx_NEWLINE_xXPatient who has received radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 25% of the bone marrow was irradiatedXx_NEWLINE_xXPatient who has received radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) or in whom >= 25% of the bone marrow was irradiatedXx_NEWLINE_xXPatients must =< 25Xx_NEWLINE_xXExtensive prior radiotherapy on more than 30% of bone marrow reserves or prior bone marrow/stem cell transplantation within 2 years before screening. Limited field radiation for ?2 weeks prior to screening period is permittedXx_NEWLINE_xXParticipants who have received prior radiation therapy to > 25% of the bone marrow.Xx_NEWLINE_xXThe patient has received radiation to ? 25% of his or her bone marrow within 4 weeks of the first dose of study drug.Xx_NEWLINE_xXReceived prior external beam radiation therapy for another reason to > 25% of active bone marrowXx_NEWLINE_xXHistory of prior whole brain radiotherapy (WBRT) other than prophylactic cranial radiation. Prophylactic cranial radiation with a maximum dose of 25 Gy delivered as 10 fractions is allowed. WBRT in excess of 25 Gy (anything over 25 Gy) is not allowedXx_NEWLINE_xXPrior treatment with radiation therapy involving >=25% of the hematopoietically active bone marrow within 3 months before the first dose of study drug.Xx_NEWLINE_xXRadiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks, or palliative radiation therapy within 2 weeks of the first dose of study drug treatment.Xx_NEWLINE_xXPatients must not have had radiotherapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapyXx_NEWLINE_xXReceived chemotherapy, radiotherapy (to more than 30% of the bone marrow or with a wide field of radiation), or biologic therapy within the last 30 daysXx_NEWLINE_xXRadiation therapy to >30% of bone marrow prior to study entry;Xx_NEWLINE_xXPrior radiation therapy for treatment of cancer is allowed to <25% of the bone marrow.Xx_NEWLINE_xXPatient who has received radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 25% of the bone marrow was irradiatedXx_NEWLINE_xXPrior external beam radiation (including brachytherapy) involving 25% of bone marrow (excluding scatter doses of =< 5 Gy)Xx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%Xx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%Xx_NEWLINE_xXPrior pelvic radiation therapy or patients who have undergone prior radiation to greater than or equal to 25% of the bone marrow within the past year are excluded; patients who received radiation for prostate cancer are also excludedXx_NEWLINE_xXPrevious total body irradiation, or irradiation of >25% of the patient's bone marrow.Xx_NEWLINE_xXPatient who has received radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 25% of the bone marrow was irradiatedXx_NEWLINE_xXHistory of radiation therapy to >= 25% of the bone marrow for other diseasesXx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrowXx_NEWLINE_xXReceived previous radiotherapy to approximately > 25% of bone marrowXx_NEWLINE_xXPrevious pelvic radiation affecting >= 25% of the bone marrow; patients who received whole pelvic radiation are excludedXx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%Xx_NEWLINE_xXPrior radiation therapy is allowed to < 25% of the bone marrow; note: no radiation therapy within 30 days prior to registration for protocol therapyXx_NEWLINE_xXPrior radiotherapy in the adjuvant setting allowed provided that less than 25% of the bone marrow had been irradiatedXx_NEWLINE_xXPrior cancer therapy with pemetrexed/cisplatin must have been completed at least 30 days prior to the first cycle of milataxel; prior radiotherapy (less than 25% of the bone marrow) must have been completed at least 30 days prior to study enrollment.Xx_NEWLINE_xXPalliative bone-directed radiotherapy is permitted unless involving an area of ? 25% of bone marrow reserves and occurring within 5 weeks prior to the start of study treatment;Xx_NEWLINE_xXReceived radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to registration, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 25 percent (%) of the bone marrow was irradiatedXx_NEWLINE_xXPatients with >= 25% of the bone marrow radiated for other diseasesXx_NEWLINE_xXPrior radiation therapy irradiating more than 10% of total bone marrowXx_NEWLINE_xXParticipants may not have had radiation to > 25% of the bone marrowXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse events have not resolved to grade 1 or less (except alopecia) from agents administered more than 4 weeks earlier; patients must have completed prior biological therapies and/or targeted therapies >= 2 weeks prior to study enrollment; patients who have had radiation to the pelvis or other bone marrow-bearing sites will be considered on a case by case basis and may be excluded if the bone marrow reserve is not considered adequate (i.e. radiation to > 25% of bone marrow)Xx_NEWLINE_xXDefinitive radiotherapy (> 10 fractions and maximal area of hematopoietic active Bone Marrow treated greater than 25%) within 4 weeks prior to ScreeningXx_NEWLINE_xXPatient who has received radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 25% of the bone marrow was irradiatedXx_NEWLINE_xXPatient who has received radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 25% of the bone marrow was irradiatedXx_NEWLINE_xXPatients who received radiotherapy to more than 25% of their bone marrowXx_NEWLINE_xXPatients who received radiotherapy to more than 25% of their bone marrowXx_NEWLINE_xXPatients with greater than 25% involvement of the bone marrow with HLXx_NEWLINE_xXPrior radiation therapy to whole pelvis or greater amount of marrow-forming boneXx_NEWLINE_xX6 weeks if other bone marrow radiation has been administered.Xx_NEWLINE_xXPatients who have received radiotherapy =< 2 weeks prior to starting study treatment and/or from whom >= 30% of the bone marrow was irradiated as determined by the investigatorXx_NEWLINE_xXPatient has received radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 30% of the bone marrow was irradiatedXx_NEWLINE_xXNo history of radiation therapy to >= 25% of the bone marrow for other diseases or history of anthracycline therapyXx_NEWLINE_xXPrior radiation therapy encompassing > 25% of bone marrowXx_NEWLINE_xXPatients must have no prior radiation therapy to >= 25% of the bone marrow for prior systemic anthracycline therapy; prior intravesical anthracycline therapy for non-muscle invasive urothelial carcinoma of the bladder is permittedXx_NEWLINE_xXPatients cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy, chronic treatment dose corticosteroids (greater than the equivalent of 10 mg prednisone per day), or radiation therapy to > 30% of the bone marrow, within 6 months of the first vaccination; treatment or salvage radiation therapy encompassing =< 30% of bone marrow must have been completed 4 weeks prior to the first vaccinationXx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%Xx_NEWLINE_xXRadiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment with the exception of patients receiving radiation to more than 30% of the bone marrow which must be completed within 4 weeks of the first dose of study treatment.Xx_NEWLINE_xXRadiotherapy to ? 25% of the bone marrow within 4 weeks prior to randomizationXx_NEWLINE_xXParticipant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow (such as, pelvic or abdominal radiation) within 30 days prior to randomizationXx_NEWLINE_xXRadiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.Xx_NEWLINE_xXPrior radiotherapy to > 25% of bone marrow; Note: standard rectal cancer chemoradiation will not exclude subject from study protocolXx_NEWLINE_xXRadiation therapy (other than palliative) =< 2 weeks prior to randomization; note: patients who have had > 25% of their functional bone marrow irradiated are not eligible for this trialXx_NEWLINE_xXPatients who had radiation to greater than 25% marrow in the past 5 yearsXx_NEWLINE_xXHas received prior radiation to > 50% of the bone marrowXx_NEWLINE_xXPrior radiation to greater than 25% of the bone marrow or whole pelvis radiationXx_NEWLINE_xXPrior radiation to greater than 25% of the bone marrow or whole pelvis radiationXx_NEWLINE_xXPatient must not have had radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%Xx_NEWLINE_xXPrior external beam radiation therapy to more than 25% of the bone marrow.Xx_NEWLINE_xXPatients may not have had prior radiotherapy to > 25% of bone marrow; standard rectal cancer chemoradiation will not exclude subject from study protocol; any radiation must have concluded >= 4 weeks prior to start of protocol treatmentXx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%; (ongoing small field radiation therapy for palliation only is allowed)Xx_NEWLINE_xXTwo weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated)Xx_NEWLINE_xXNo prior radiation therapy to > 25% of bone marrow forming bones (i.e., pelvis) within 30 days prior to registration for protocol therapy. See Study Procedures Manual to calculate percent of prior radiation.Xx_NEWLINE_xXTwo weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated)Xx_NEWLINE_xXPrior radiation therapy is allowed provided exposure does not exceed an area of 25% of marrow space and occurred ? 6 weeks prior to the first dose of MEDI-551 (Arm A only)Xx_NEWLINE_xXPatients who have received radiation to more than 25% of marrow-bearing areasXx_NEWLINE_xXRadiation therapy to greater than 25% of the bone marrowXx_NEWLINE_xXPatients who have had radiation to the pelvis or other bone marrow-bearing sites will be considered on a case by case basis and may be excluded if the bone marrow reserve is not considered adequate (> 25% of bone marrow)Xx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrow (note: whole pelvic radiation is considered to be over 25%)Xx_NEWLINE_xXNo prior radiation therapy to the whole pelvis or to ?25% of the total bone marrow area.Xx_NEWLINE_xXSubjects with a history of prior radiotherapy are eligible if they meet the following parameters: Prior to study treatment administration, must be ? 21 days post-therapy and have recovered from all toxicities; must have evidence of measurable disease outside the radiation fields or radiologically confirmed progression of disease; must not have had > 25% of their functional bone marrow irradiated. Must have radiologically measureable disease, a life expectancy > 12 weeks, and adequate organ function.Xx_NEWLINE_xXprior radiation therapy with volume of bone marrow treated over 25%.Xx_NEWLINE_xXPatients cannot receive concomitant radiation therapy at enrollment; while on protocol limited palliative radiotherapy extending over a small bone marrow field (10%) is allowedXx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%Xx_NEWLINE_xXPalliative radiation therapy (RT) for metastatic disease is allowed only if =< 25% of total body bone marrow was irradiated and < or = 35Gy administered to the pericardial area; 28 days must have elapsed since completion of RT with bone marrow recovery; soft tissue disease irradiated in the prior 2 months may not be designated as measurable diseaseXx_NEWLINE_xXPrior radiation therapy allowed to < 25% of the bone marrowXx_NEWLINE_xXRadiotherapy involving <25% of the hematopoietically active bone marrow within 21 days preceding first dose of study treatmentXx_NEWLINE_xXRadiotherapy involving ?25% of the hematopoietically active bone marrow within 42 days preceding first dose of study treatmentXx_NEWLINE_xXPrior radiotherapy to > 25% of bone marrow volume.Xx_NEWLINE_xXPrior treatment with radiation therapy involving ? 25% of the hematopoietically active bone marrow within 42 days before the first dose of study drug.Xx_NEWLINE_xXPrior treatment with radiation therapy involving >= 25 percent (%) of hematopoietically active bone marrow.Xx_NEWLINE_xXFocal radiation therapy within 14 days prior to randomization; radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (i.e., prior radiation must have been to less than 30% of the bone marrow)Xx_NEWLINE_xXPrior treatment with radiation therapy involving ? 25% of the hematopoietically active bone marrowXx_NEWLINE_xXPatients who have received definitive radiotherapy ? 4 weeks prior to starting study drug, who have not recovered from side effects of such therapy and/or from whom ? 30% of the bone marrow was irradiated.Xx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%Xx_NEWLINE_xXRadiation therapy to 25% of bone marrow within 2 weeks of first doseXx_NEWLINE_xXFocal radiation therapy within 7 days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (i.e., prior radiation must have been to less than 30% of the bone marrow).Xx_NEWLINE_xXPatients must have had at least 1 prior systemic chemotherapy (not just steroids or local radiation); last chemotherapy or radiation must be at least 4 weeks prior to enrollment on this study; patients who decline other potentially curative therapy may be eligible; prior radiation therapy must not have been to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%Xx_NEWLINE_xXIrradiation to more than 25% of bone marrow-bearing areasXx_NEWLINE_xXReceived radiation therapy to more than 25% of the bone marrow-containing spaces < 84 days prior to first dose of study medicationXx_NEWLINE_xXPrevious radiation therapy is allowed to less than 25% of the bone marrow, but should have been limited and must not have included whole pelvis radiation.Xx_NEWLINE_xXPrior radiation therapy to < 25% of the bone marrow [see bone marrow radiation chart in the study procedure manual (SPM)] allowed if completed within 30 days prior to registration for protocol therapy.Xx_NEWLINE_xXPrior radiation to ? 30% of bone marrow or any radiation therapy within 28 days prior to randomizationXx_NEWLINE_xXPatients who have had radiation to the pelvis or other bone marrow-bearing sites will be considered on a case by case basis and may be excluded if the bone marrow reserve is not considered adequate (> 25% of bone marrow irradiated)Xx_NEWLINE_xXRadiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%Xx_NEWLINE_xXStage II Arm B: prior CDK4/6 inhibitor treatment, bone marrow transplant or extensive radiotherapy to ?25% of bone marrowXx_NEWLINE_xXPrior radiation therapy is allowed; patients must not have received any radiation within 3 weeks prior to the initiation of study treatment; patients may not have areas of irradiated marrow exceeding 40% of bone marrow volumeXx_NEWLINE_xXRadiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug treatment, or palliative radiation therapy within 2 weeks of the first dose of study drug treatmentXx_NEWLINE_xXPrior treatment with radiation therapy involving greater than or equal to (>=) 25% of the hematopoietically active bone marrow.Xx_NEWLINE_xXThe patient has received radiation to ? 25% of his or her bone marrow within 4 weeks of the first dose of study drug.Xx_NEWLINE_xX